GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » PS Ratio

Sino Biopharmaceutical (Sino Biopharmaceutical) PS Ratio

: 1.60 (As of Today)
View and export this data going back to 2010. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sino Biopharmaceutical's share price is $0.31495. Sino Biopharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.20. Hence, Sino Biopharmaceutical's PS Ratio for today is 1.60.

Good Sign:

Sino Biopharmaceutical Ltd stock PS Ratio (=1.37) is close to 10-year low of 1.37

The historical rank and industry rank for Sino Biopharmaceutical's PS Ratio or its related term are showing as below:

SBMFF' s PS Ratio Range Over the Past 10 Years
Min: 1.43   Med: 3.37   Max: 8.21
Current: 1.43

During the past 13 years, Sino Biopharmaceutical's highest PS Ratio was 8.21. The lowest was 1.43. And the median was 3.37.

SBMFF's PS Ratio is ranked better than
89.06% of 996 companies
in the Biotechnology industry
Industry Median: 8.985 vs SBMFF: 1.43

Sino Biopharmaceutical's Revenue per Sharefor the six months ended in Jun. 2023 was $0.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.20.

Warning Sign:

Sino Biopharmaceutical Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Sino Biopharmaceutical was -1.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 5.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 9.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.60% per year.

During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 64.10% per year. The lowest was -36.70% per year. And the median was 16.30% per year.

Back to Basics: PS Ratio


Sino Biopharmaceutical PS Ratio Historical Data

The historical data trend for Sino Biopharmaceutical's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.07 5.06 3.20 2.70 2.12

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 - 2.70 - -

Competitive Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's PS Ratio falls into.



Sino Biopharmaceutical PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sino Biopharmaceutical's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.31495/0.197
=1.60

Sino Biopharmaceutical's Share Price of today is $0.31495.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sino Biopharmaceutical  (OTCPK:SBMFF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sino Biopharmaceutical PS Ratio Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines

From GuruFocus

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019